𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Condom use promotes regression of human papillomavirus–associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia

✍ Scribed by Maaike C.G. Bleeker; Cornelis J.A. Hogewoning; Feja J. Voorhorst; Adriaan J.C. van den Brule; Peter J.F. Snijders; Theo M. Starink; Johannes Berkhof; Chris J.L.M. Meijer


Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
149 KB
Volume
107
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Penile HPV‐associated lesions are frequently seen in male sexual partners of women with CIN. The natural course and clinical significance of these lesions are unclear. Women with CIN and their male sexual partners were randomized for condom use (condom group n = 68, noncondom group n = 68). Males were screened for the presence of penile lesions, i.e., flat lesions, papular lesions and condylomata acuminata, and of HPV in their penile swabs by PCR testing. Median follow‐up time was 13.1 months (range 2.9–57.4). The outcome of our study was clinical regression of penile lesions defined as disappearance of lesions at penoscopy. Potentially prognostic factors, i.e., HPV status, lesion type and age, were studied as well. Outcomes were assessed in 57 men of the condom group and in 43 men of the noncondom group. Condom use shortened the median time to regression of flat penile lesions (7.4 months condom group vs. 13.9 months noncondom group; HR = 2.1, 95% CI 1.2–3.7). This effect was not found for papular lesions (HR = 0.5, 95% CI 0.1–2.8). HPV‐negative men showed a significantly shorter median time to regression of flat lesions (3.8 months) compared to men with either HPV‐positive status (8.5 months; HR = 0.4, 95% CI 0.2–0.9) or inconsistent HPV status (13.1 months; HR = 0.2, 95% CI 0.1–0.6). Regression of flat penile lesions is HPV‐dependent and accelerated by condom use. This effect is probably the result of blocking viral transmission between sexual partners. © 2003 Wiley‐Liss, Inc.